摘要
Bronchial artery infusion(BAI)with chemical agents was performed in 41 patients with lung carcinoma up to 61times,included 33 cases(51 times)primary lung carcinoma(PLC)and 8cases(10 times)lung metastatic carcinoma (LMC). Short-time effects were valuable in 31 cases with PLC and 7 cases with LMC.Complete remission(CR)plus partial rimission(PR)ocurred in 14 cases(45.16%)among 31 patients with PLC and 1 case(14.28%)among 14 patients with LMC(P<0 .01).CR plus PR was 10cases(52.63%)among 19 patients with central type cancer (CTC)and 4 cases (33.33%) among 12 patients with perprephal type cancer(PTC) of PLC(P<0.05). CR plus PR in 15 squamous carcinomas(SC),6 adenocarcinomas (AC)2 small cell undifferentiated carcinomas(SCLC)and 8 histologically unclassfied carcinomas(HUC)were 8(53.33%),1(50%),and 3(37.5%), respectively.The rate of CR plus PR in squamous carcinoma was higher than that in adenocarcinoma and histologically unclassified carcinoma(P<0.05).There was no remarkable difference in CR plus PR among stage Ⅱ-Ⅲand Ⅳpatients with PLC, CAP and FMP protocol treatment.This study also investigated and analysed the side effects of 41 patients by BAI treatment.
Bronchial artery infusion(BAI)with chemical agents was performed in 41 patients with lung carcinoma up to 61times,included 33 cases(51 times)primary lung carcinoma(PLC)and 8cases(10 times)lung metastatic carcinoma (LMC). Short-time effects were valuable in 31 cases with PLC and 7 cases with LMC.Complete remission(CR)plus partial rimission(PR)ocurred in 14 cases(45.16%)among 31 patients with PLC and 1 case(14.28%)among 14 patients with LMC(P<0 .01).CR plus PR was 10cases(52.63%)among 19 patients with central type cancer (CTC)and 4 cases (33.33%) among 12 patients with perprephal type cancer(PTC) of PLC(P<0.05). CR plus PR in 15 squamous carcinomas(SC),6 adenocarcinomas (AC)2 small cell undifferentiated carcinomas(SCLC)and 8 histologically unclassfied carcinomas(HUC)were 8(53.33%),1(50%),and 3(37.5%), respectively.The rate of CR plus PR in squamous carcinoma was higher than that in adenocarcinoma and histologically unclassified carcinoma(P<0.05).There was no remarkable difference in CR plus PR among stage Ⅱ-Ⅲand Ⅳpatients with PLC, CAP and FMP protocol treatment.This study also investigated and analysed the side effects of 41 patients by BAI treatment.
